{"success":true,"data":{"pressRelease":{"id":"134901","rtpr_id":"nPn9H14J3a","ticker":"INSM","exchange":"NASDAQ","all_tickers":["INSM"],"title":"Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026","author":"PR Newswire","published_at":"2026-09-03T11:00:05.651Z","article_body":"Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026\n\nPR Newswire\n\nBRIDGEWATER, N.J., Sept. 3, 2026\n\n—New Data Explore Efficacy and Safety of BRINSUPRI (®) (brensocatib) in\nPatients With Non-Cystic Fibrosis Bronchiectasis (NCFB) and History of\nNontuberculous Mycobacterial (NTM) Lung Disease—\n\n—New Research Examines Treprostinil Palmitil Inhalation Powder (TPIP) via\nCOMPERA 2.0 Risk Assessment in Pulmonary Arterial Hypertension (PAH)—\n\nBRIDGEWATER, N.J., Sept. 3, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq:\nINSM), a people-first global biopharmaceutical company striving to deliver\nfirst- and best-in-class therapies to transform the lives of patients facing\nserious diseases, today announced that five abstracts highlighting data from\nits respiratory portfolio have been accepted for presentation at the European\nRespiratory Society (ERS) Congress 2026 taking place Sept. 5–9, 2026, in\nBarcelona.\n\nPresentation highlights include a late-breaking abstract from the Phase 3b\nENCORE study, which evaluated 12 months of treatment with\nARIKAYCE(®) (amikacin liposome inhalation suspension) plus multidrug therapy\n(azithromycin 250 mg and ethambutol 15 mg/kg) in patients diagnosed with a new\noccurrence of Mycobacterium avium complex (MAC) lung infection who had not\nreceived antibiotics. The scientific program will also include a post hoc\nanalysis of COMPERA 2.0 risk score data from the Phase 2 study of treprostinil\npalmitil inhalation powder (TPIP) in patients with pulmonary arterial\nhypertension (PAH). Additionally, data will be presented on the psychosocial\nburden of exacerbations, treatment patterns, and healthcare resource\nutilization associated with bronchiectasis, as well as from a post hoc\nanalysis of the Phase 3 ASPEN study of BRINSUPRI(®) (brensocatib), the first\nand only approved treatment for non-cystic fibrosis bronchiectasis (NCFB).\n\n\"The data presented at the ERS Congress 2026 reflect our commitment to\nadvancing research and improving outcomes for patients with serious\nrespiratory diseases,\" said Martina Flammer, M.D., MBA, Chief Medical Officer\nof Insmed. \"We are particularly pleased to present findings from our Phase 3b\nENCORE study addressing rates of recurrence following treatment for NTM lung\ndisease, an important challenge in long-term disease management. These\nfindings, together with data from our broader respiratory portfolio,\ncontribute to a growing body of evidence that can help shape the future of\ncare for patients who have long faced limited treatment options.\"\n\nPresentations:\n\nOral Session OA1207, Sunday, Sept. 6, 9:30 a.m. CEST to 10:45 a.m. CEST (3:30\na.m. ET to 4:45 a.m. ET)\n\n * Late-Breaking Abstract:\nMicrobiologic Outcomes and Recurrence in Patients With Newly Diagnosed\nMycobacterium avium Complex Lung Disease (MACLD) in the Phase 3b ENCORE Trial\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=1224491385&u=https%3A%2F%2Flive.ersnet.org%2Fpag%2Fpresentation%2F581122%3Fview%3Dlist%26segment%3Dposters%26sort%3Dref%26q%3DMicrobiologic%2BOutcomes%2Band%2BRecurrence%2Bin%2BPatients%2BWith%2BNewly%2BDiagnosed%2BMycobacterium%2Bavium%2BComplex%2BLung%2BDisease%2B%2528MACLD%2529%2Bin%2Bthe%2BPhase%2B3b%2BENCORE%2BTrial%2B&a=Microbiologic+Outcomes+and+Recurrence+in+Patients+With+Newly+Diagnosed+Mycobacterium+avium+Complex+Lung+Disease+(MACLD)+in+the+Phase+3b+ENCORE+Trial)\nPoster Session PA908, Sunday, Sept. 6, 8:00 a.m. CEST to 9:30 a.m. CEST (2:00\na.m. ET to 3:30 a.m. ET)\n\n * COMPERA 2.0 Risk Assessment of Treprostinil Palmitil Inhalation Powder (TPIP)\nfor Pulmonary Arterial Hypertension (PAH): A Post Hoc Analysis of a Phase 2\nStudy\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=3770488755&u=https%3A%2F%2Flive.ersnet.org%2Fpag%2Fpresentation%2F574788%3Fview%3Dlist%26segment%3Dposters%26sort%3Dref%26q%3DCOMPERA%2B2.0%2BRisk%2BAssessment%2Bof%2BTreprostinil%2BPalmitil%2BInhalation%2BPowder%2B%2528TPIP%2529%2Bfor%2BPulmonary%2BArterial%2BHypertension%2B%2528PAH%2529%253A%2BA%2BPost%2BHoc%2BAnalysis%2Bof%2Ba%2BPhase%2B2%2BStudy%2B&a=COMPERA+2.0+Risk+Assessment+of+Treprostinil+Palmitil+Inhalation+Powder+(TPIP)+for+Pulmonary+Arterial+Hypertension+(PAH)%3A+A+Post+Hoc+Analysis+of+a+Phase+2+Study)\nPoster Session PA1839, Sunday, Sept. 6, 12:30 p.m. CEST to 2:00 p.m. CEST\n(6:30 a.m. ET to 8:00 a.m. ET)\n\n * Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB) and\nHistory of Nontuberculous Mycobacteria (NTM) Infection: A Post Hoc Analysis of\nthe ASPEN Trial\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=1082642660&u=https%3A%2F%2Flive.ersnet.org%2Fpag%2Fpresentation%2F575458%3Fview%3Dlist%26segment%3Dposters%26sort%3Dref%26q%3DBrensocatib%2Bin%2BPatients%2BWith%2BNon-Cystic%2BFibrosis%2BBronchiectasis%2B%2528NCFB%2529%2Band%2BHistory%2Bof%2BNontuberculous%2BMycobacteria%2B%2528NTM%2529%2BInfection%253A%2BA%2BPost%2BHoc%2BAnalysis%2Bof%2Bthe%2BASPEN%2BTrial%2B&a=Brensocatib+in+Patients+With+Non-Cystic+Fibrosis+Bronchiectasis+(NCFB)+and+History+of+Nontuberculous+Mycobacteria+(NTM)+Infection%3A+A+Post+Hoc+Analysis+of+the+ASPEN+Trial)\nPoster Session PA1840, Sunday, Sept. 6, 12:30 p.m. CEST to 2:00 p.m. CEST\n(6:30 a.m. ET to 8:00 a.m. ET)\n\n * Quantifying the Psychosocial Impact of Exacerbations in Bronchiectasis: A\nEuropean Patient-Centered Study\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=2669025385&u=https%3A%2F%2Flive.ersnet.org%2Fpag%2Fpresentation%2F575459%3Fview%3Dlist%26segment%3Dposters%26sort%3Dref%26q%3DQuantifying%2Bthe%2BPsychosocial%2BImpact%2Bof%2BExacerbations%2Bin%2BBronchiectasis%253A%2BA%2BEuropean%2BPatient-Centered%2BStudy%2B&a=Quantifying+the+Psychosocial+Impact+of+Exacerbations+in+Bronchiectasis%3A+A+European+Patient-Centered+Study)\nPoster Session PA2883, Monday, Sept. 7, 8:00 a.m. CEST to 9:00 a.m. CEST (2:00\na.m. ET to 3:00 a.m. ET)\n\n * Treatment Patterns and Healthcare Resource Utilization Associated With\nBronchiectasis and Pulmonary Exacerbations in Spain\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=3987377658&u=https%3A%2F%2Flive.ersnet.org%2Fpag%2Fpresentation%2F576296%3Fview%3Dlist%26segment%3Dposters%26sort%3Dref%26q%3DTreatment%2BPatterns%2Band%2BHealthcare%2BResource%2BUtilization%2BAssociated%2BWith%2BBronchiectasis%2Band%2BPulmonary%2BExacerbations%2Bin%2BSpain%2B&a=Treatment+Patterns+and+Healthcare+Resource+Utilization+Associated+With+Bronchiectasis+and+Pulmonary+Exacerbations+in+Spain)\nAbout ARIKAYCE\n\nARIKAYCE(®) is approved in the United States as ARIKAYCE (amikacin\nliposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590\nmg Nebuliser Dispersion, and in Japan as ARIKAYCE inhalation 590 mg\n(amikacin sulfate inhalation drug product). Current international treatment\nguidelines recommend the use of ARIKAYCE for appropriate patients. ARIKAYCE is\na novel, inhaled, once-daily formulation of amikacin, an established\nantibiotic that was historically administered intravenously and associated\nwith severe toxicity to hearing, balance, and kidney function. Insmed's\nproprietary PULMOVANCE™ liposomal technology enables the delivery of\namikacin directly to the lungs, where liposomal amikacin is taken up by lung\nmacrophages where the infection resides, while limiting systemic exposure.\nARIKAYCE is administered once daily using the Lamira(®) Nebulizer System\nmanufactured by PARI Pharma GmbH (PARI).\n\nAbout PARI Pharma and the Lamira(®) Nebulizer System\n\nARIKAYCE is delivered by a novel inhalation device, the Lamira(®) Nebulizer\nSystem, developed by PARI. Lamira(®) is a quiet, portable nebulizer that\nenables efficient aerosolization of ARIKAYCE via a vibrating, perforated\nmembrane. Based on PARI's 100-year history working with aerosols, PARI is\ndedicated to advancing inhalation therapies by developing innovative delivery\nplatforms to improve patient care.\n\nAbout BRINSUPRI\n\nBRINSUPRI(®) (brensocatib) is a small molecule, once-daily, oral, reversible\ninhibitor of dipeptidyl peptidase 1 (DPP1), designed to inhibit the activation\nof enzymes (neutrophil serine proteases) in neutrophils that are key drivers\nof chronic airway inflammation in NCFB. The therapy is approved in the United\nStates as BRINSUPRI (brensocatib 10 mg and 25 mg tablets) and indicated for\nthe treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and\npediatric patients 12 years of age or older. In the European Union and United\nKingdom, BRINSUPRI (brensocatib 25 mg tablets) is approved for the treatment\nof NCFB in patients 12 years of age and older with two or more exacerbations\nin the prior 12 months. In Japan, BRINSUPRI (brensocatib 25 mg tablets) is\napproved for the treatment of patients with non-cystic fibrosis bronchiectasis\n(NCFB) in adult and pediatric patients 12 years and older.\n\nAbout TPIP\n\nTreprostinil palmitil inhalation powder (TPIP) is an investigational dry\npowder formulation of treprostinil palmitil, a treprostinil prodrug consisting\nof treprostinil linked by an ester bond to a 16-carbon chain. Designed\nentirely in Insmed's laboratories, TPIP is a potentially highly differentiated\nprostanoid being developed as once-daily therapy for the treatment of patients\nwith pulmonary arterial hypertension (PAH), pulmonary hypertension associated\nwith interstitial lung disease (PH-ILD), progressive pulmonary fibrosis (PPF),\nand idiopathic pulmonary fibrosis (IPF). TPIP is administered in a\ncapsule-based inhalation device. TPIP is an investigational drug product that\nhas not been approved for any indication in any jurisdiction.\n\nBOXED WARNING AND IMPORTANT SAFETY INFORMATION FOR ARIKAYCE IN THE U.S.\n WARNING: RISK OF INCREASED RESPIRATORY ADVERSE REACTIONS\n\nARIKAYCE has been associated with an increased risk of respiratory adverse\n reactions,\n including hypersensitivity pneumonitis, hemoptysis, bronchospasm, and\n exacerbation of\n underlying pulmonary disease that have led to hospitalizations in some cases.\n\nHypersensitivity Pneumonitis has been reported with the use of ARIKAYCE in\nthe clinical trials. Hypersensitivity pneumonitis (reported as allergic\nalveolitis, pneumonitis, interstitial lung disease, allergic reaction to\nARIKAYCE) was reported at a higher frequency in patients treated with ARIKAYCE\nplus background regimen (3.1%) compared to patients treated with a background\nregimen alone (0%). Most patients with hypersensitivity pneumonitis\ndiscontinued treatment with ARIKAYCE and received treatment with\ncorticosteroids. If hypersensitivity pneumonitis occurs, discontinue ARIKAYCE\nand manage patients as medically appropriate.\n\nHemoptysis has been reported with the use of ARIKAYCE in the clinical trials.\nHemoptysis was reported at a higher frequency in patients treated with\nARIKAYCE plus background regimen (17.9%) compared to patients treated with a\nbackground regimen alone (12.5%). If hemoptysis occurs, manage patients as\nmedically appropriate.\n\nBronchospasm has been reported with the use of ARIKAYCE in the clinical\ntrials. Bronchospasm (reported as asthma, bronchial hyperreactivity,\nbronchospasm, dyspnea, dyspnea exertional, prolonged expiration, throat\ntightness, wheezing) was reported at a higher frequency in patients treated\nwith ARIKAYCE plus background regimen (28.7%) compared to patients treated\nwith a background regimen alone (10.7%). If bronchospasm occurs during the use\nof ARIKAYCE, treat patients as medically appropriate.\n\nExacerbations of underlying pulmonary disease has been reported with the use\nof ARIKAYCE in the clinical trials. Exacerbations of underlying pulmonary\ndisease (reported as chronic obstructive pulmonary disease (COPD), infective\nexacerbation of COPD, infective exacerbation of bronchiectasis) have been\nreported at a higher frequency in patients treated with ARIKAYCE plus\nbackground regimen (14.8%) compared to patients treated with background\nregimen alone (9.8%). If exacerbations of underlying pulmonary disease occur\nduring the use of ARIKAYCE, treat patients as medically appropriate.\n\nAnaphylaxis and Hypersensitivity Reactions: Serious and potentially\nlife-threatening hypersensitivity reactions, including anaphylaxis, have been\nreported in patients taking ARIKAYCE. Signs and symptoms include acute onset\nof skin and mucosal tissue hypersensitivity reactions (hives, itching,\nflushing, swollen lips/tongue/uvula), respiratory difficulty (shortness of\nbreath, wheezing, stridor, cough), gastrointestinal symptoms (nausea,\nvomiting, diarrhea, crampy abdominal pain), and cardiovascular signs and\nsymptoms of anaphylaxis (tachycardia, low blood pressure, syncope,\nincontinence, dizziness). Before therapy with ARIKAYCE is instituted, evaluate\nfor previous hypersensitivity reactions to aminoglycosides. If anaphylaxis or\na hypersensitivity reaction occurs, discontinue ARIKAYCE and institute\nappropriate supportive measures.\n\nOtotoxicity has been reported with the use of ARIKAYCE in the clinical\ntrials. Ototoxicity (including deafness, dizziness, presyncope, tinnitus, and\nvertigo) were reported with a higher frequency in patients treated with\nARIKAYCE plus background regimen (17%) compared to patients treated with\nbackground regimen alone (9.8%). This was primarily driven by tinnitus (7.6%\nin ARIKAYCE plus background regimen vs 0.9% in the background regimen alone\narm) and dizziness (6.3% in ARIKAYCE plus background regimen vs 2.7% in the\nbackground regimen alone arm). Closely monitor patients with known or\nsuspected auditory or vestibular dysfunction during treatment with ARIKAYCE.\nIf ototoxicity occurs, manage patients as medically appropriate, including\npotentially discontinuing ARIKAYCE.\n\nNephrotoxicity was observed during the clinical trials of ARIKAYCE in\npatients with MAC lung disease but not at a higher frequency than background\nregimen alone. Nephrotoxicity has been associated with the aminoglycosides.\nClose monitoring of patients with known or suspected renal dysfunction may be\nneeded when prescribing ARIKAYCE.\n\nNeuromuscular Blockade: Patients with neuromuscular disorders were not\nenrolled in ARIKAYCE clinical trials. Patients with known or suspected\nneuromuscular disorders, such as myasthenia gravis, should be closely\nmonitored since aminoglycosides may aggravate muscle weakness by blocking the\nrelease of acetylcholine at neuromuscular junctions.\n\nEmbryo-Fetal Toxicity: Aminoglycosides can cause fetal harm when administered\nto a pregnant woman. Aminoglycosides, including ARIKAYCE, may be associated\nwith total, irreversible, bilateral congenital deafness in pediatric patients\nexposed in utero. Patients who use ARIKAYCE during pregnancy, or become\npregnant while taking ARIKAYCE should be apprised of the potential hazard to\nthe fetus.\n\nContraindications: ARIKAYCE is contraindicated in patients with known\nhypersensitivity to any aminoglycoside.\n\nMost Common Adverse Reactions: The most common adverse reactions in Trial 1 at\nan incidence ≥5% for patients using ARIKAYCE plus background regimen\ncompared to patients treated with background regimen alone were dysphonia (47%\nvs 1%), cough (39% vs 17%), bronchospasm (29% vs 11%), hemoptysis (18% vs\n13%), ototoxicity (17% vs 10%), upper airway irritation (17% vs 2%),\nmusculoskeletal pain (17% vs 8%), fatigue and asthenia (16% vs 10%),\nexacerbation of underlying pulmonary disease (15% vs 10%), diarrhea (13% vs\n5%), nausea (12% vs 4%), pneumonia (10% vs 8%), headache (10% vs 5%), pyrexia\n(7% vs 5%), vomiting (7% vs 4%), rash (6% vs 2%), decreased weight (6% vs 1%),\nchange in sputum (5% vs 1%), and chest discomfort (5% vs 3%).\n\nDrug Interactions: Avoid concomitant use of ARIKAYCE with medications\nassociated with neurotoxicity, nephrotoxicity, and ototoxicity. Some diuretics\ncan enhance aminoglycoside toxicity by altering aminoglycoside concentrations\nin serum and tissue. Avoid concomitant use of ARIKAYCE with ethacrynic acid,\nfurosemide, urea, or intravenous mannitol.\n\nOverdosage: Adverse reactions specifically associated with overdose of\nARIKAYCE have not been identified. Acute toxicity should be treated with\nimmediate withdrawal of ARIKAYCE, and baseline tests of renal function should\nbe undertaken. Hemodialysis may be helpful in removing amikacin from the body.\nIn all cases of suspected overdosage, physicians should contact the Regional\nPoison Control Center for information about effective treatment.\n\nU.S. INDICATION\n\nLIMITED POPULATION: ARIKAYCE(®) is indicated in adults, who have limited or\nno alternative treatment options, for the treatment of Mycobacterium\navium complex (MAC) lung disease as part of a combination antibacterial drug\nregimen in patients who do not achieve negative sputum cultures after a\nminimum of 6 consecutive months of a multidrug background regimen therapy. As\nonly limited clinical safety and effectiveness data for ARIKAYCE are currently\navailable, reserve ARIKAYCE for use in adults who have limited or no\nalternative treatment options. This drug is indicated for use in a limited and\nspecific population of patients.\n\nThis indication is approved under accelerated approval based on achieving\nsputum culture conversion (defined as 3 consecutive negative monthly sputum\ncultures) by Month 6. Clinical benefit has not yet been established. Continued\napproval for this indication may be contingent upon verification and\ndescription of clinical benefit in confirmatory trials.\n\nLimitation of Use:\n\nARIKAYCE has only been studied in patients with refractory MAC lung disease\ndefined as patients who did not achieve negative sputum cultures after a\nminimum of 6 consecutive months of a multidrug background regimen therapy. The\nuse of ARIKAYCE is not recommended for patients with non-refractory MAC lung\ndisease.\n\nPatients are encouraged to report negative side effects of prescription drugs\nto the FDA.\nVisit www.fda.gov/medwatch\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=1483022616&u=https%3A%2F%2Fwww.fda.gov%2Fmedwatch&a=www.fda.gov%2Fmedwatch)\n, or call 1‑800‑FDA‑1088. You can also call the Company at\n1-844-4-INSMED.\n\nPlease see Full Prescribing Information\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=1244204356&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4592125-1%26h%3D1433129124%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4390270-1%2526h%253D1989839444%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D2382278-1%252526h%25253D2359604135%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D2339048-1%25252526h%2525253D3665684709%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fwww.arikayce.com%252525252Fpdf%252525252Ffull-prescribing-information.pdf%25252526a%2525253DFull%2525252BPrescribing%2525252BInformation%252526a%25253DFull%25252BPrescribing%25252BInformation%2526a%253DFull%252BPrescribing%252BInformation%26a%3DFull%2BPrescribing%2BInformation&a=Full+Prescribing+Information)\n.\n\nINDICATION AND IMPORTANT SAFETY INFORMATION FOR BRINSUPRI IN THE U.S.\n\nU.S. Indication\n\nBRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis\n(NCFB) in adult and pediatric patients 12 years of age and older.\n\nImportant Safety Information\n\nWARNINGS AND PRECAUTIONS\n\nDermatologic Adverse Reactions\nTreatment with BRINSUPRI is associated with an increase in dermatologic\nadverse reactions, including rash, dry skin, and hyperkeratosis. Monitor\npatients for development of new rashes or skin conditions and refer patients\nto a dermatologist for evaluation of new dermatologic findings.\n\nGingival and Periodontal Adverse Reactions\nTreatment with BRINSUPRI is associated with an increase in gingival and\nperiodontal adverse reactions. Refer patients to dental care services for\nregular dental checkups while taking BRINSUPRI. Advise patients to perform\nroutine dental hygiene.\n\nLive Attenuated Vaccines\nIt is unknown whether administration of live attenuated vaccines during\nBRINSUPRI treatment will affect the safety or effectiveness of these vaccines.\nThe use of live attenuated vaccines should be avoided in patients receiving\nBRINSUPRI.\n\nADVERSE REACTIONS\nThe most common adverse reactions ≥2% in the ASPEN trial included upper\nrespiratory tract infection, headache, rash, dry skin, hyperkeratosis, and\nhypertension. The safety profile for adult patients with NCFB in WILLOW was\ngenerally similar to ASPEN, except for a higher incidence of gingival and\nperiodontal adverse reactions.\n\nLess Common Adverse Reactions\nLiver Function Test Elevations\nIn ASPEN, there was an increase from baseline in average ALT, AST, and\nalkaline phosphatase levels at all time points from Week 4 through Week 56 in\nboth BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT\n>3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence of\nAST >3X ULN was 0.2%, 0.3%, and 0.5%; and the incidence of alkaline\nphosphatase >1.5X ULN was 2.5%, 4.1%, and 4.0% in patients treated with\nplacebo and BRINSUPRI 10 mg and 25 mg, respectively.\n\nSkin Cancers\nIn ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI\n10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in\nplacebo-treated patients.\n\nAlopecia\nIn ASPEN, the incidence of alopecia among patients treated with BRINSUPRI 10\nmg and 25 mg was 1.5% and 1.6%, respectively, compared to 0.4% in\nplacebo-treated patients.\n\nUSE IN SPECIFIC POPULATIONS\n\nPregnancy: There are no clinical data on the use of BRINSUPRI in pregnant\nwomen.\n\nLactation: There is no information regarding the presence of BRINSUPRI and/or\nits metabolite(s) in human milk, the effects on the breastfed infant, or the\neffects on milk production. The developmental and health benefits of\nbreastfeeding should be considered along with the mother's clinical need for\nBRINSUPRI and any potential adverse effects on the breastfed child from\nBRINSUPRI or from the underlying maternal condition.\n\nPediatric use: The safety and effectiveness of BRINSUPRI for the treatment of\nNCFB have been established in pediatric patients aged 12 years and older.\nCommon adverse reactions in pediatric patients aged 12 years and older\nenrolled in ASPEN were consistent with those in adults. The safety and\neffectiveness of BRINSUPRI have not been established in pediatric patients\nyounger than 12 years of age.\n\nPlease see full US Prescribing Information\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=2707062411&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4592125-1%26h%3D68188934%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4479882-1%2526h%253D3802583368%2526u%253Dhttps%25253A%25252F%25252Finsmed.com%25252Fbrinsupri_full_prescribing_information%2526a%253DPrescribing%252BInformation%26a%3DUS%2BPrescribing%2BInformation&a=US+Prescribing+Information)\n.\n\nAbout Insmed\n\nInsmed Incorporated is a people-first global biopharmaceutical company\nstriving to deliver first- and best-in-class therapies to transform the lives\nof patients facing serious diseases. The Company is advancing a diverse\nportfolio of approved and mid- to late-stage investigational medicines —\nincluding two approved therapies to treat chronic, debilitating lung diseases\n— as well as cutting-edge drug discovery focused on serving patient\ncommunities where the need is greatest. Insmed's commercial portfolio and\nclinical pipeline are organized around three therapeutic areas: Respiratory,\nImmunology & Inflammation, and Neuro & Other Rare. The Company's\nresearch engine is advancing a wide range of technologies and modalities,\nincluding gene therapy, AI-driven protein engineering, RNA end-joining, and\nsynthetic rescue, in the pursuit of future pipeline candidates.\n\nHeadquartered in Bridgewater, New Jersey, Insmed has offices and research\nlocations throughout the United States, Europe, and Japan. Insmed is proud to\nbe recognized as one of the best employers in the biopharmaceutical industry,\nincluding spending five consecutive years as the No. 1 Science Top Employer.\nVisit www.insmed.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=1867517815&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4703288-1%26h%3D1989777388%26u%3Dhttp%253A%252F%252Fwww.insmed.com%252F%26a%3Dwww.insmed.com&a=www.insmed.com)\nto learn more or follow us on LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=1280003178&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4703288-1%26h%3D3771540838%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Finsmed%26a%3DLinkedIn&a=LinkedIn)\n, Instagram\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=3480041779&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4703288-1%26h%3D3370096843%26u%3Dhttps%253A%252F%252Fwww.instagram.com%252FInsmed%252F%26a%3DInstagram&a=Instagram)\n, YouTube\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=3987369054&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4703288-1%26h%3D2114749782%26u%3Dhttps%253A%252F%252Fwww.youtube.com%252F%2540insmed%26a%3DYouTube&a=YouTube)\n, and X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=1409499462&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4703288-1%26h%3D3482314689%26u%3Dhttps%253A%252F%252Fx.com%252FInsmed%26a%3DX&a=X)\n.\n\nForward-looking Statements\n\nThis press release contains forward-looking statements that involve\nsubstantial risks and uncertainties. \"Forward-looking statements,\" as that\nterm is defined in the Private Securities Litigation Reform Act of 1995, are\nstatements that are not historical facts and involve a number of risks and\nuncertainties. Words herein such as \"may,\" \"will,\" \"should,\" \"could,\" \"would,\"\n\"expects,\" \"plans,\" \"anticipates,\" \"believes,\" \"estimates,\" \"projects,\"\n\"predicts,\" \"intends,\" \"potential,\" \"continues,\" and similar expressions (as\nwell as other words or expressions referencing future events, conditions or\ncircumstances) may identify forward-looking statements.\n\nThe forward-looking statements in this press release are based upon the\nCompany's current expectations and beliefs, and involve known and unknown\nrisks, uncertainties and other factors, which may cause the Company's actual\nresults, performance and achievements and the timing of certain events to\ndiffer materially from the results, performance, achievements or timings\ndiscussed, projected, anticipated or indicated in any forward-looking\nstatements. Such risks, uncertainties and other factors include, among others,\nthe following: risk that interim, topline or preliminary data from our\nclinical trials that we announce or publish from time to time may change as\nmore patient data become available or may be interpreted differently if\nadditional data are disclosed; failure to successfully conduct future clinical\ntrials for our marketed products or our product candidates and our potential\ninability to enroll or retain sufficient patients to conduct and complete the\ntrials or generate data necessary for regulatory approval of our product\ncandidates; development of unexpected safety or efficacy concerns related to\nour marketed products or our product candidates; risks that our clinical\nstudies will be delayed, that serious side effects will be identified during\ndrug development, or that any protocol amendments submitted will be rejected;\nfailure to maintain U.S., European or Japanese approval for ARIKAYCE or U.S.\nor European approval for BRINSUPRI; our inability to obtain full approval of\nARIKAYCE from the FDA or our failure to obtain regulatory approval to expand\nARIKAYCE's indication to a broader patient population; failure to obtain, or\ndelays in obtaining, regulatory approvals for our product candidates in the\nU.S., Europe or Japan, for ARIKAYCE outside of the U.S., Europe and Japan,\nincluding separate regulatory approval for the Lamira(®) Nebulizer System in\neach market and for each usage, or for BRINSUPRI outside of the U.S. and\nEurope; and failure to successfully commercialize our product candidates, if\napproved by applicable regulatory authorities, or to maintain applicable\nregulatory approvals for our product candidates, if approved.\n\nThe Company may not actually achieve the results, plans, intentions or\nexpectations indicated by the Company's forward-looking statements because, by\ntheir nature, forward-looking statements involve risks and uncertainties\nbecause they relate to events and depend on circumstances that may or may not\noccur in the future. For additional information about the risks and\nuncertainties that may affect the Company's business, please see the factors\ndiscussed in Item 1A, \"Risk Factors,\" in the Company's Annual Report on Form\n10-K for the year ended December 31, 2025 and any subsequent Company filings\nwith the Securities and Exchange Commission (SEC).\n\nThe Company cautions readers not to place undue reliance on any such\nforward-looking statements, which speak only as of the date of this press\nrelease. The Company disclaims any obligation, except as specifically required\nby law and the rules of the SEC, to publicly update or revise any such\nstatements to reflect any change in expectations or in events, conditions or\ncircumstances on which any such statements may be based, or that may affect\nthe likelihood that actual results will differ from those set forth in the\nforward-looking statements.\n\nContact:\n\nInvestors:\nSara Bonstein\nChief Financial Officer\ninvestor.relations@insmed.com (mailto:investor.relations@insmed.com)\n\nMedia:\nClaire Mulhearn\nVice President, Corporate Communications\nmedia@insmed.com (mailto:media@insmed.com)\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/insmed-to-present-data-across-its-respiratory-portfolio-including-new-late-breaking-arikayce-amikacin-liposome-inhalation-suspension-results-from-phase-3b-encore-study-at-the-european-respiratory-society-congress-2026-302868119.html\n(https://www.prnewswire.com/news-releases/insmed-to-present-data-across-its-respiratory-portfolio-including-new-late-breaking-arikayce-amikacin-liposome-inhalation-suspension-results-from-phase-3b-encore-study-at-the-european-respiratory-society-congress-2026-302868119.html)\n\nSOURCE Insmed Incorporated\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1109455/Insmed-Incorporated-Logo.jpg?id=OA2926621\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9H14J3a","title":"Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026","author":"PR Newswire","ticker":"INSM","created":"2026-09-03T11:00:05.651Z","tickers":["INSM"],"exchange":"NASDAQ","article_body":"Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026\n\nPR Newswire\n\nBRIDGEWATER, N.J., Sept. 3, 2026\n\n—New Data Explore Efficacy and Safety of BRINSUPRI (®) (brensocatib) in\nPatients With Non-Cystic Fibrosis Bronchiectasis (NCFB) and History of\nNontuberculous Mycobacterial (NTM) Lung Disease—\n\n—New Research Examines Treprostinil Palmitil Inhalation Powder (TPIP) via\nCOMPERA 2.0 Risk Assessment in Pulmonary Arterial Hypertension (PAH)—\n\nBRIDGEWATER, N.J., Sept. 3, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq:\nINSM), a people-first global biopharmaceutical company striving to deliver\nfirst- and best-in-class therapies to transform the lives of patients facing\nserious diseases, today announced that five abstracts highlighting data from\nits respiratory portfolio have been accepted for presentation at the European\nRespiratory Society (ERS) Congress 2026 taking place Sept. 5–9, 2026, in\nBarcelona.\n\nPresentation highlights include a late-breaking abstract from the Phase 3b\nENCORE study, which evaluated 12 months of treatment with\nARIKAYCE(®) (amikacin liposome inhalation suspension) plus multidrug therapy\n(azithromycin 250 mg and ethambutol 15 mg/kg) in patients diagnosed with a new\noccurrence of Mycobacterium avium complex (MAC) lung infection who had not\nreceived antibiotics. The scientific program will also include a post hoc\nanalysis of COMPERA 2.0 risk score data from the Phase 2 study of treprostinil\npalmitil inhalation powder (TPIP) in patients with pulmonary arterial\nhypertension (PAH). Additionally, data will be presented on the psychosocial\nburden of exacerbations, treatment patterns, and healthcare resource\nutilization associated with bronchiectasis, as well as from a post hoc\nanalysis of the Phase 3 ASPEN study of BRINSUPRI(®) (brensocatib), the first\nand only approved treatment for non-cystic fibrosis bronchiectasis (NCFB).\n\n\"The data presented at the ERS Congress 2026 reflect our commitment to\nadvancing research and improving outcomes for patients with serious\nrespiratory diseases,\" said Martina Flammer, M.D., MBA, Chief Medical Officer\nof Insmed. \"We are particularly pleased to present findings from our Phase 3b\nENCORE study addressing rates of recurrence following treatment for NTM lung\ndisease, an important challenge in long-term disease management. These\nfindings, together with data from our broader respiratory portfolio,\ncontribute to a growing body of evidence that can help shape the future of\ncare for patients who have long faced limited treatment options.\"\n\nPresentations:\n\nOral Session OA1207, Sunday, Sept. 6, 9:30 a.m. CEST to 10:45 a.m. CEST (3:30\na.m. ET to 4:45 a.m. ET)\n\n * Late-Breaking Abstract:\nMicrobiologic Outcomes and Recurrence in Patients With Newly Diagnosed\nMycobacterium avium Complex Lung Disease (MACLD) in the Phase 3b ENCORE Trial\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=1224491385&u=https%3A%2F%2Flive.ersnet.org%2Fpag%2Fpresentation%2F581122%3Fview%3Dlist%26segment%3Dposters%26sort%3Dref%26q%3DMicrobiologic%2BOutcomes%2Band%2BRecurrence%2Bin%2BPatients%2BWith%2BNewly%2BDiagnosed%2BMycobacterium%2Bavium%2BComplex%2BLung%2BDisease%2B%2528MACLD%2529%2Bin%2Bthe%2BPhase%2B3b%2BENCORE%2BTrial%2B&a=Microbiologic+Outcomes+and+Recurrence+in+Patients+With+Newly+Diagnosed+Mycobacterium+avium+Complex+Lung+Disease+(MACLD)+in+the+Phase+3b+ENCORE+Trial)\nPoster Session PA908, Sunday, Sept. 6, 8:00 a.m. CEST to 9:30 a.m. CEST (2:00\na.m. ET to 3:30 a.m. ET)\n\n * COMPERA 2.0 Risk Assessment of Treprostinil Palmitil Inhalation Powder (TPIP)\nfor Pulmonary Arterial Hypertension (PAH): A Post Hoc Analysis of a Phase 2\nStudy\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=3770488755&u=https%3A%2F%2Flive.ersnet.org%2Fpag%2Fpresentation%2F574788%3Fview%3Dlist%26segment%3Dposters%26sort%3Dref%26q%3DCOMPERA%2B2.0%2BRisk%2BAssessment%2Bof%2BTreprostinil%2BPalmitil%2BInhalation%2BPowder%2B%2528TPIP%2529%2Bfor%2BPulmonary%2BArterial%2BHypertension%2B%2528PAH%2529%253A%2BA%2BPost%2BHoc%2BAnalysis%2Bof%2Ba%2BPhase%2B2%2BStudy%2B&a=COMPERA+2.0+Risk+Assessment+of+Treprostinil+Palmitil+Inhalation+Powder+(TPIP)+for+Pulmonary+Arterial+Hypertension+(PAH)%3A+A+Post+Hoc+Analysis+of+a+Phase+2+Study)\nPoster Session PA1839, Sunday, Sept. 6, 12:30 p.m. CEST to 2:00 p.m. CEST\n(6:30 a.m. ET to 8:00 a.m. ET)\n\n * Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB) and\nHistory of Nontuberculous Mycobacteria (NTM) Infection: A Post Hoc Analysis of\nthe ASPEN Trial\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=1082642660&u=https%3A%2F%2Flive.ersnet.org%2Fpag%2Fpresentation%2F575458%3Fview%3Dlist%26segment%3Dposters%26sort%3Dref%26q%3DBrensocatib%2Bin%2BPatients%2BWith%2BNon-Cystic%2BFibrosis%2BBronchiectasis%2B%2528NCFB%2529%2Band%2BHistory%2Bof%2BNontuberculous%2BMycobacteria%2B%2528NTM%2529%2BInfection%253A%2BA%2BPost%2BHoc%2BAnalysis%2Bof%2Bthe%2BASPEN%2BTrial%2B&a=Brensocatib+in+Patients+With+Non-Cystic+Fibrosis+Bronchiectasis+(NCFB)+and+History+of+Nontuberculous+Mycobacteria+(NTM)+Infection%3A+A+Post+Hoc+Analysis+of+the+ASPEN+Trial)\nPoster Session PA1840, Sunday, Sept. 6, 12:30 p.m. CEST to 2:00 p.m. CEST\n(6:30 a.m. ET to 8:00 a.m. ET)\n\n * Quantifying the Psychosocial Impact of Exacerbations in Bronchiectasis: A\nEuropean Patient-Centered Study\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=2669025385&u=https%3A%2F%2Flive.ersnet.org%2Fpag%2Fpresentation%2F575459%3Fview%3Dlist%26segment%3Dposters%26sort%3Dref%26q%3DQuantifying%2Bthe%2BPsychosocial%2BImpact%2Bof%2BExacerbations%2Bin%2BBronchiectasis%253A%2BA%2BEuropean%2BPatient-Centered%2BStudy%2B&a=Quantifying+the+Psychosocial+Impact+of+Exacerbations+in+Bronchiectasis%3A+A+European+Patient-Centered+Study)\nPoster Session PA2883, Monday, Sept. 7, 8:00 a.m. CEST to 9:00 a.m. CEST (2:00\na.m. ET to 3:00 a.m. ET)\n\n * Treatment Patterns and Healthcare Resource Utilization Associated With\nBronchiectasis and Pulmonary Exacerbations in Spain\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=3987377658&u=https%3A%2F%2Flive.ersnet.org%2Fpag%2Fpresentation%2F576296%3Fview%3Dlist%26segment%3Dposters%26sort%3Dref%26q%3DTreatment%2BPatterns%2Band%2BHealthcare%2BResource%2BUtilization%2BAssociated%2BWith%2BBronchiectasis%2Band%2BPulmonary%2BExacerbations%2Bin%2BSpain%2B&a=Treatment+Patterns+and+Healthcare+Resource+Utilization+Associated+With+Bronchiectasis+and+Pulmonary+Exacerbations+in+Spain)\nAbout ARIKAYCE\n\nARIKAYCE(®) is approved in the United States as ARIKAYCE (amikacin\nliposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590\nmg Nebuliser Dispersion, and in Japan as ARIKAYCE inhalation 590 mg\n(amikacin sulfate inhalation drug product). Current international treatment\nguidelines recommend the use of ARIKAYCE for appropriate patients. ARIKAYCE is\na novel, inhaled, once-daily formulation of amikacin, an established\nantibiotic that was historically administered intravenously and associated\nwith severe toxicity to hearing, balance, and kidney function. Insmed's\nproprietary PULMOVANCE™ liposomal technology enables the delivery of\namikacin directly to the lungs, where liposomal amikacin is taken up by lung\nmacrophages where the infection resides, while limiting systemic exposure.\nARIKAYCE is administered once daily using the Lamira(®) Nebulizer System\nmanufactured by PARI Pharma GmbH (PARI).\n\nAbout PARI Pharma and the Lamira(®) Nebulizer System\n\nARIKAYCE is delivered by a novel inhalation device, the Lamira(®) Nebulizer\nSystem, developed by PARI. Lamira(®) is a quiet, portable nebulizer that\nenables efficient aerosolization of ARIKAYCE via a vibrating, perforated\nmembrane. Based on PARI's 100-year history working with aerosols, PARI is\ndedicated to advancing inhalation therapies by developing innovative delivery\nplatforms to improve patient care.\n\nAbout BRINSUPRI\n\nBRINSUPRI(®) (brensocatib) is a small molecule, once-daily, oral, reversible\ninhibitor of dipeptidyl peptidase 1 (DPP1), designed to inhibit the activation\nof enzymes (neutrophil serine proteases) in neutrophils that are key drivers\nof chronic airway inflammation in NCFB. The therapy is approved in the United\nStates as BRINSUPRI (brensocatib 10 mg and 25 mg tablets) and indicated for\nthe treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and\npediatric patients 12 years of age or older. In the European Union and United\nKingdom, BRINSUPRI (brensocatib 25 mg tablets) is approved for the treatment\nof NCFB in patients 12 years of age and older with two or more exacerbations\nin the prior 12 months. In Japan, BRINSUPRI (brensocatib 25 mg tablets) is\napproved for the treatment of patients with non-cystic fibrosis bronchiectasis\n(NCFB) in adult and pediatric patients 12 years and older.\n\nAbout TPIP\n\nTreprostinil palmitil inhalation powder (TPIP) is an investigational dry\npowder formulation of treprostinil palmitil, a treprostinil prodrug consisting\nof treprostinil linked by an ester bond to a 16-carbon chain. Designed\nentirely in Insmed's laboratories, TPIP is a potentially highly differentiated\nprostanoid being developed as once-daily therapy for the treatment of patients\nwith pulmonary arterial hypertension (PAH), pulmonary hypertension associated\nwith interstitial lung disease (PH-ILD), progressive pulmonary fibrosis (PPF),\nand idiopathic pulmonary fibrosis (IPF). TPIP is administered in a\ncapsule-based inhalation device. TPIP is an investigational drug product that\nhas not been approved for any indication in any jurisdiction.\n\nBOXED WARNING AND IMPORTANT SAFETY INFORMATION FOR ARIKAYCE IN THE U.S.\n WARNING: RISK OF INCREASED RESPIRATORY ADVERSE REACTIONS\n\nARIKAYCE has been associated with an increased risk of respiratory adverse\n reactions,\n including hypersensitivity pneumonitis, hemoptysis, bronchospasm, and\n exacerbation of\n underlying pulmonary disease that have led to hospitalizations in some cases.\n\nHypersensitivity Pneumonitis has been reported with the use of ARIKAYCE in\nthe clinical trials. Hypersensitivity pneumonitis (reported as allergic\nalveolitis, pneumonitis, interstitial lung disease, allergic reaction to\nARIKAYCE) was reported at a higher frequency in patients treated with ARIKAYCE\nplus background regimen (3.1%) compared to patients treated with a background\nregimen alone (0%). Most patients with hypersensitivity pneumonitis\ndiscontinued treatment with ARIKAYCE and received treatment with\ncorticosteroids. If hypersensitivity pneumonitis occurs, discontinue ARIKAYCE\nand manage patients as medically appropriate.\n\nHemoptysis has been reported with the use of ARIKAYCE in the clinical trials.\nHemoptysis was reported at a higher frequency in patients treated with\nARIKAYCE plus background regimen (17.9%) compared to patients treated with a\nbackground regimen alone (12.5%). If hemoptysis occurs, manage patients as\nmedically appropriate.\n\nBronchospasm has been reported with the use of ARIKAYCE in the clinical\ntrials. Bronchospasm (reported as asthma, bronchial hyperreactivity,\nbronchospasm, dyspnea, dyspnea exertional, prolonged expiration, throat\ntightness, wheezing) was reported at a higher frequency in patients treated\nwith ARIKAYCE plus background regimen (28.7%) compared to patients treated\nwith a background regimen alone (10.7%). If bronchospasm occurs during the use\nof ARIKAYCE, treat patients as medically appropriate.\n\nExacerbations of underlying pulmonary disease has been reported with the use\nof ARIKAYCE in the clinical trials. Exacerbations of underlying pulmonary\ndisease (reported as chronic obstructive pulmonary disease (COPD), infective\nexacerbation of COPD, infective exacerbation of bronchiectasis) have been\nreported at a higher frequency in patients treated with ARIKAYCE plus\nbackground regimen (14.8%) compared to patients treated with background\nregimen alone (9.8%). If exacerbations of underlying pulmonary disease occur\nduring the use of ARIKAYCE, treat patients as medically appropriate.\n\nAnaphylaxis and Hypersensitivity Reactions: Serious and potentially\nlife-threatening hypersensitivity reactions, including anaphylaxis, have been\nreported in patients taking ARIKAYCE. Signs and symptoms include acute onset\nof skin and mucosal tissue hypersensitivity reactions (hives, itching,\nflushing, swollen lips/tongue/uvula), respiratory difficulty (shortness of\nbreath, wheezing, stridor, cough), gastrointestinal symptoms (nausea,\nvomiting, diarrhea, crampy abdominal pain), and cardiovascular signs and\nsymptoms of anaphylaxis (tachycardia, low blood pressure, syncope,\nincontinence, dizziness). Before therapy with ARIKAYCE is instituted, evaluate\nfor previous hypersensitivity reactions to aminoglycosides. If anaphylaxis or\na hypersensitivity reaction occurs, discontinue ARIKAYCE and institute\nappropriate supportive measures.\n\nOtotoxicity has been reported with the use of ARIKAYCE in the clinical\ntrials. Ototoxicity (including deafness, dizziness, presyncope, tinnitus, and\nvertigo) were reported with a higher frequency in patients treated with\nARIKAYCE plus background regimen (17%) compared to patients treated with\nbackground regimen alone (9.8%). This was primarily driven by tinnitus (7.6%\nin ARIKAYCE plus background regimen vs 0.9% in the background regimen alone\narm) and dizziness (6.3% in ARIKAYCE plus background regimen vs 2.7% in the\nbackground regimen alone arm). Closely monitor patients with known or\nsuspected auditory or vestibular dysfunction during treatment with ARIKAYCE.\nIf ototoxicity occurs, manage patients as medically appropriate, including\npotentially discontinuing ARIKAYCE.\n\nNephrotoxicity was observed during the clinical trials of ARIKAYCE in\npatients with MAC lung disease but not at a higher frequency than background\nregimen alone. Nephrotoxicity has been associated with the aminoglycosides.\nClose monitoring of patients with known or suspected renal dysfunction may be\nneeded when prescribing ARIKAYCE.\n\nNeuromuscular Blockade: Patients with neuromuscular disorders were not\nenrolled in ARIKAYCE clinical trials. Patients with known or suspected\nneuromuscular disorders, such as myasthenia gravis, should be closely\nmonitored since aminoglycosides may aggravate muscle weakness by blocking the\nrelease of acetylcholine at neuromuscular junctions.\n\nEmbryo-Fetal Toxicity: Aminoglycosides can cause fetal harm when administered\nto a pregnant woman. Aminoglycosides, including ARIKAYCE, may be associated\nwith total, irreversible, bilateral congenital deafness in pediatric patients\nexposed in utero. Patients who use ARIKAYCE during pregnancy, or become\npregnant while taking ARIKAYCE should be apprised of the potential hazard to\nthe fetus.\n\nContraindications: ARIKAYCE is contraindicated in patients with known\nhypersensitivity to any aminoglycoside.\n\nMost Common Adverse Reactions: The most common adverse reactions in Trial 1 at\nan incidence ≥5% for patients using ARIKAYCE plus background regimen\ncompared to patients treated with background regimen alone were dysphonia (47%\nvs 1%), cough (39% vs 17%), bronchospasm (29% vs 11%), hemoptysis (18% vs\n13%), ototoxicity (17% vs 10%), upper airway irritation (17% vs 2%),\nmusculoskeletal pain (17% vs 8%), fatigue and asthenia (16% vs 10%),\nexacerbation of underlying pulmonary disease (15% vs 10%), diarrhea (13% vs\n5%), nausea (12% vs 4%), pneumonia (10% vs 8%), headache (10% vs 5%), pyrexia\n(7% vs 5%), vomiting (7% vs 4%), rash (6% vs 2%), decreased weight (6% vs 1%),\nchange in sputum (5% vs 1%), and chest discomfort (5% vs 3%).\n\nDrug Interactions: Avoid concomitant use of ARIKAYCE with medications\nassociated with neurotoxicity, nephrotoxicity, and ototoxicity. Some diuretics\ncan enhance aminoglycoside toxicity by altering aminoglycoside concentrations\nin serum and tissue. Avoid concomitant use of ARIKAYCE with ethacrynic acid,\nfurosemide, urea, or intravenous mannitol.\n\nOverdosage: Adverse reactions specifically associated with overdose of\nARIKAYCE have not been identified. Acute toxicity should be treated with\nimmediate withdrawal of ARIKAYCE, and baseline tests of renal function should\nbe undertaken. Hemodialysis may be helpful in removing amikacin from the body.\nIn all cases of suspected overdosage, physicians should contact the Regional\nPoison Control Center for information about effective treatment.\n\nU.S. INDICATION\n\nLIMITED POPULATION: ARIKAYCE(®) is indicated in adults, who have limited or\nno alternative treatment options, for the treatment of Mycobacterium\navium complex (MAC) lung disease as part of a combination antibacterial drug\nregimen in patients who do not achieve negative sputum cultures after a\nminimum of 6 consecutive months of a multidrug background regimen therapy. As\nonly limited clinical safety and effectiveness data for ARIKAYCE are currently\navailable, reserve ARIKAYCE for use in adults who have limited or no\nalternative treatment options. This drug is indicated for use in a limited and\nspecific population of patients.\n\nThis indication is approved under accelerated approval based on achieving\nsputum culture conversion (defined as 3 consecutive negative monthly sputum\ncultures) by Month 6. Clinical benefit has not yet been established. Continued\napproval for this indication may be contingent upon verification and\ndescription of clinical benefit in confirmatory trials.\n\nLimitation of Use:\n\nARIKAYCE has only been studied in patients with refractory MAC lung disease\ndefined as patients who did not achieve negative sputum cultures after a\nminimum of 6 consecutive months of a multidrug background regimen therapy. The\nuse of ARIKAYCE is not recommended for patients with non-refractory MAC lung\ndisease.\n\nPatients are encouraged to report negative side effects of prescription drugs\nto the FDA.\nVisit www.fda.gov/medwatch\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=1483022616&u=https%3A%2F%2Fwww.fda.gov%2Fmedwatch&a=www.fda.gov%2Fmedwatch)\n, or call 1‑800‑FDA‑1088. You can also call the Company at\n1-844-4-INSMED.\n\nPlease see Full Prescribing Information\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=1244204356&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4592125-1%26h%3D1433129124%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4390270-1%2526h%253D1989839444%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D2382278-1%252526h%25253D2359604135%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D2339048-1%25252526h%2525253D3665684709%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fwww.arikayce.com%252525252Fpdf%252525252Ffull-prescribing-information.pdf%25252526a%2525253DFull%2525252BPrescribing%2525252BInformation%252526a%25253DFull%25252BPrescribing%25252BInformation%2526a%253DFull%252BPrescribing%252BInformation%26a%3DFull%2BPrescribing%2BInformation&a=Full+Prescribing+Information)\n.\n\nINDICATION AND IMPORTANT SAFETY INFORMATION FOR BRINSUPRI IN THE U.S.\n\nU.S. Indication\n\nBRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis\n(NCFB) in adult and pediatric patients 12 years of age and older.\n\nImportant Safety Information\n\nWARNINGS AND PRECAUTIONS\n\nDermatologic Adverse Reactions\nTreatment with BRINSUPRI is associated with an increase in dermatologic\nadverse reactions, including rash, dry skin, and hyperkeratosis. Monitor\npatients for development of new rashes or skin conditions and refer patients\nto a dermatologist for evaluation of new dermatologic findings.\n\nGingival and Periodontal Adverse Reactions\nTreatment with BRINSUPRI is associated with an increase in gingival and\nperiodontal adverse reactions. Refer patients to dental care services for\nregular dental checkups while taking BRINSUPRI. Advise patients to perform\nroutine dental hygiene.\n\nLive Attenuated Vaccines\nIt is unknown whether administration of live attenuated vaccines during\nBRINSUPRI treatment will affect the safety or effectiveness of these vaccines.\nThe use of live attenuated vaccines should be avoided in patients receiving\nBRINSUPRI.\n\nADVERSE REACTIONS\nThe most common adverse reactions ≥2% in the ASPEN trial included upper\nrespiratory tract infection, headache, rash, dry skin, hyperkeratosis, and\nhypertension. The safety profile for adult patients with NCFB in WILLOW was\ngenerally similar to ASPEN, except for a higher incidence of gingival and\nperiodontal adverse reactions.\n\nLess Common Adverse Reactions\nLiver Function Test Elevations\nIn ASPEN, there was an increase from baseline in average ALT, AST, and\nalkaline phosphatase levels at all time points from Week 4 through Week 56 in\nboth BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT\n>3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence of\nAST >3X ULN was 0.2%, 0.3%, and 0.5%; and the incidence of alkaline\nphosphatase >1.5X ULN was 2.5%, 4.1%, and 4.0% in patients treated with\nplacebo and BRINSUPRI 10 mg and 25 mg, respectively.\n\nSkin Cancers\nIn ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI\n10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in\nplacebo-treated patients.\n\nAlopecia\nIn ASPEN, the incidence of alopecia among patients treated with BRINSUPRI 10\nmg and 25 mg was 1.5% and 1.6%, respectively, compared to 0.4% in\nplacebo-treated patients.\n\nUSE IN SPECIFIC POPULATIONS\n\nPregnancy: There are no clinical data on the use of BRINSUPRI in pregnant\nwomen.\n\nLactation: There is no information regarding the presence of BRINSUPRI and/or\nits metabolite(s) in human milk, the effects on the breastfed infant, or the\neffects on milk production. The developmental and health benefits of\nbreastfeeding should be considered along with the mother's clinical need for\nBRINSUPRI and any potential adverse effects on the breastfed child from\nBRINSUPRI or from the underlying maternal condition.\n\nPediatric use: The safety and effectiveness of BRINSUPRI for the treatment of\nNCFB have been established in pediatric patients aged 12 years and older.\nCommon adverse reactions in pediatric patients aged 12 years and older\nenrolled in ASPEN were consistent with those in adults. The safety and\neffectiveness of BRINSUPRI have not been established in pediatric patients\nyounger than 12 years of age.\n\nPlease see full US Prescribing Information\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=2707062411&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4592125-1%26h%3D68188934%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4479882-1%2526h%253D3802583368%2526u%253Dhttps%25253A%25252F%25252Finsmed.com%25252Fbrinsupri_full_prescribing_information%2526a%253DPrescribing%252BInformation%26a%3DUS%2BPrescribing%2BInformation&a=US+Prescribing+Information)\n.\n\nAbout Insmed\n\nInsmed Incorporated is a people-first global biopharmaceutical company\nstriving to deliver first- and best-in-class therapies to transform the lives\nof patients facing serious diseases. The Company is advancing a diverse\nportfolio of approved and mid- to late-stage investigational medicines —\nincluding two approved therapies to treat chronic, debilitating lung diseases\n— as well as cutting-edge drug discovery focused on serving patient\ncommunities where the need is greatest. Insmed's commercial portfolio and\nclinical pipeline are organized around three therapeutic areas: Respiratory,\nImmunology & Inflammation, and Neuro & Other Rare. The Company's\nresearch engine is advancing a wide range of technologies and modalities,\nincluding gene therapy, AI-driven protein engineering, RNA end-joining, and\nsynthetic rescue, in the pursuit of future pipeline candidates.\n\nHeadquartered in Bridgewater, New Jersey, Insmed has offices and research\nlocations throughout the United States, Europe, and Japan. Insmed is proud to\nbe recognized as one of the best employers in the biopharmaceutical industry,\nincluding spending five consecutive years as the No. 1 Science Top Employer.\nVisit www.insmed.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=1867517815&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4703288-1%26h%3D1989777388%26u%3Dhttp%253A%252F%252Fwww.insmed.com%252F%26a%3Dwww.insmed.com&a=www.insmed.com)\nto learn more or follow us on LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=1280003178&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4703288-1%26h%3D3771540838%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Finsmed%26a%3DLinkedIn&a=LinkedIn)\n, Instagram\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=3480041779&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4703288-1%26h%3D3370096843%26u%3Dhttps%253A%252F%252Fwww.instagram.com%252FInsmed%252F%26a%3DInstagram&a=Instagram)\n, YouTube\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=3987369054&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4703288-1%26h%3D2114749782%26u%3Dhttps%253A%252F%252Fwww.youtube.com%252F%2540insmed%26a%3DYouTube&a=YouTube)\n, and X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766149-1&h=1409499462&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4703288-1%26h%3D3482314689%26u%3Dhttps%253A%252F%252Fx.com%252FInsmed%26a%3DX&a=X)\n.\n\nForward-looking Statements\n\nThis press release contains forward-looking statements that involve\nsubstantial risks and uncertainties. \"Forward-looking statements,\" as that\nterm is defined in the Private Securities Litigation Reform Act of 1995, are\nstatements that are not historical facts and involve a number of risks and\nuncertainties. Words herein such as \"may,\" \"will,\" \"should,\" \"could,\" \"would,\"\n\"expects,\" \"plans,\" \"anticipates,\" \"believes,\" \"estimates,\" \"projects,\"\n\"predicts,\" \"intends,\" \"potential,\" \"continues,\" and similar expressions (as\nwell as other words or expressions referencing future events, conditions or\ncircumstances) may identify forward-looking statements.\n\nThe forward-looking statements in this press release are based upon the\nCompany's current expectations and beliefs, and involve known and unknown\nrisks, uncertainties and other factors, which may cause the Company's actual\nresults, performance and achievements and the timing of certain events to\ndiffer materially from the results, performance, achievements or timings\ndiscussed, projected, anticipated or indicated in any forward-looking\nstatements. Such risks, uncertainties and other factors include, among others,\nthe following: risk that interim, topline or preliminary data from our\nclinical trials that we announce or publish from time to time may change as\nmore patient data become available or may be interpreted differently if\nadditional data are disclosed; failure to successfully conduct future clinical\ntrials for our marketed products or our product candidates and our potential\ninability to enroll or retain sufficient patients to conduct and complete the\ntrials or generate data necessary for regulatory approval of our product\ncandidates; development of unexpected safety or efficacy concerns related to\nour marketed products or our product candidates; risks that our clinical\nstudies will be delayed, that serious side effects will be identified during\ndrug development, or that any protocol amendments submitted will be rejected;\nfailure to maintain U.S., European or Japanese approval for ARIKAYCE or U.S.\nor European approval for BRINSUPRI; our inability to obtain full approval of\nARIKAYCE from the FDA or our failure to obtain regulatory approval to expand\nARIKAYCE's indication to a broader patient population; failure to obtain, or\ndelays in obtaining, regulatory approvals for our product candidates in the\nU.S., Europe or Japan, for ARIKAYCE outside of the U.S., Europe and Japan,\nincluding separate regulatory approval for the Lamira(®) Nebulizer System in\neach market and for each usage, or for BRINSUPRI outside of the U.S. and\nEurope; and failure to successfully commercialize our product candidates, if\napproved by applicable regulatory authorities, or to maintain applicable\nregulatory approvals for our product candidates, if approved.\n\nThe Company may not actually achieve the results, plans, intentions or\nexpectations indicated by the Company's forward-looking statements because, by\ntheir nature, forward-looking statements involve risks and uncertainties\nbecause they relate to events and depend on circumstances that may or may not\noccur in the future. For additional information about the risks and\nuncertainties that may affect the Company's business, please see the factors\ndiscussed in Item 1A, \"Risk Factors,\" in the Company's Annual Report on Form\n10-K for the year ended December 31, 2025 and any subsequent Company filings\nwith the Securities and Exchange Commission (SEC).\n\nThe Company cautions readers not to place undue reliance on any such\nforward-looking statements, which speak only as of the date of this press\nrelease. The Company disclaims any obligation, except as specifically required\nby law and the rules of the SEC, to publicly update or revise any such\nstatements to reflect any change in expectations or in events, conditions or\ncircumstances on which any such statements may be based, or that may affect\nthe likelihood that actual results will differ from those set forth in the\nforward-looking statements.\n\nContact:\n\nInvestors:\nSara Bonstein\nChief Financial Officer\ninvestor.relations@insmed.com (mailto:investor.relations@insmed.com)\n\nMedia:\nClaire Mulhearn\nVice President, Corporate Communications\nmedia@insmed.com (mailto:media@insmed.com)\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/insmed-to-present-data-across-its-respiratory-portfolio-including-new-late-breaking-arikayce-amikacin-liposome-inhalation-suspension-results-from-phase-3b-encore-study-at-the-european-respiratory-society-congress-2026-302868119.html\n(https://www.prnewswire.com/news-releases/insmed-to-present-data-across-its-respiratory-portfolio-including-new-late-breaking-arikayce-amikacin-liposome-inhalation-suspension-results-from-phase-3b-encore-study-at-the-european-respiratory-society-congress-2026-302868119.html)\n\nSOURCE Insmed Incorporated\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1109455/Insmed-Incorporated-Logo.jpg?id=OA2926621\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-03T11:00:05.719643976Z","server_sent_at_ms":1788433205719},"received_at":"2026-09-03T11:00:05.888Z","source_url":"https://www.prnewswire.com/news-releases/insmed-to-present-data-across-its-respiratory-portfolio-including-new-late-breaking-arikayce-amikacin-liposome-inhalation-suspension-results-from-phase-3b-encore-study-at-the-european-respiratory-society-congress-2026-302868119.html"},"analysis":{"id":"123787","press_release_id":"134901","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Actual ENCORE data withheld until the Sept. 6 oral session — readout risk remains","ARIKAYCE U.S. indication remains a limited population under accelerated approval; clinical benefit not yet established and confirmatory data are contingent for continued approval","TPIP remains investigational with no approval in any jurisdiction"],"eventType":"clinical_trial","narrative":"Insmed said five abstracts from its respiratory portfolio were accepted for presentation at the European Respiratory Society Congress 2026, held Sept. 5-9 in Barcelona, headlined by late-breaking Phase 3b ENCORE data for ARIKAYCE in newly diagnosed Mycobacterium avium complex lung disease.\n\nThe program also includes a post hoc COMPERA 2.0 risk analysis of the Phase 2 TPIP study in pulmonary arterial hypertension and post hoc ASPEN trial data for BRINSUPRI in bronchiectasis patients with a history of NTM infection, plus disease-burden and resource-utilization analyses.\n\nNo results were disclosed ahead of the sessions; the ENCORE findings address recurrence rates after NTM treatment, and ARIKAYCE remains under FDA accelerated approval with clinical benefit not yet established.","sentiment":"neutral","agentHooks":{"shouldPost":true,"suggestedAngle":"Catalyst watch: INSM's late-breaking Phase 3b ENCORE ARIKAYCE data drop Sept. 6 at ERS — a key read for the accelerated-approval and label-expansion story."},"keyFigures":{"drugName":"ARIKAYCE (amikacin liposome inhalation suspension)","phaseOfTrial":"Phase 3b","customDimensions":{"congress":"European Respiratory Society (ERS) Congress 2026","congress_dates":"Sept. 5-9, 2026, Barcelona","encore_regimen":"ARIKAYCE plus azithromycin 250 mg and ethambutol 15 mg/kg","abstracts_accepted":5,"encore_treatment_duration_months":12}},"quotedText":"The data presented at the ERS Congress 2026 reflect our commitment to\nadvancing research and improving outcomes for patients with serious\nrespiratory diseases","namedEntities":{"people":[{"name":"Martina Flammer, M.D., MBA","role":"Chief Medical Officer of Insmed"},{"name":"Sara Bonstein","role":"Chief Financial Officer (investor contact)"},{"name":"Claire Mulhearn","role":"Vice President, Corporate Communications (media contact)"}],"products":["ARIKAYCE (amikacin liposome inhalation suspension)","BRINSUPRI (brensocatib)","TPIP (treprostinil palmitil inhalation powder)","Lamira Nebulizer System","PULMOVANCE liposomal technology"],"companies":[{"name":"Insmed Incorporated","ticker":"INSM","relationship":"filer"},{"name":"PARI Pharma GmbH","relationship":"device partner (Lamira Nebulizer System manufacturer)"},{"name":"European Respiratory Society","relationship":"congress organizer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"This is a congress-preview announcement: five abstracts accepted at ERS 2026 with no actual results disclosed. It carries modest relevance because the late-breaking Phase 3b ENCORE data addresses NTM recurrence and ARIKAYCE's accelerated-approval/label story, but the release itself contains no directional data."},"tickerRelevance":{"others":[],"primary":"INSM"},"globalImportance":25,"audienceRelevance":40,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid/large-cap commercial-stage biotech","eventGravity":"conference data preview — no results disclosed","issuerAuthored":true,"catalystProximity":"late-breaking ENCORE data presented Sept. 6, three days after release","retailFavoriteBoost":"moderate — INSM has an active biotech retail following around ARIKAYCE/BRINSUPRI/TPIP catalysts"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Insmed said five abstracts from its respiratory portfolio were accepted for presentation at the European Respiratory Society Congress 2026, held Sept. 5-9 in Barcelona, headlined by late-breaking Phase 3b ENCORE data for ARIKAYCE in newly diagnosed Mycobacterium avium complex lung disease.\n\nThe program also includes a post hoc COMPERA 2.0 risk analysis of the Phase 2 TPIP study in pulmonary arterial hypertension and post hoc ASPEN trial data for BRINSUPRI in bronchiectasis patients with a history of NTM infection, plus disease-burden and resource-utilization analyses.\n\nNo results were disclosed ahead of the sessions; the ENCORE findings address recurrence rates after NTM treatment, and ARIKAYCE remains under FDA accelerated approval with clinical benefit not yet established.","key_figures":{"drugName":"ARIKAYCE (amikacin liposome inhalation suspension)","phaseOfTrial":"Phase 3b","customDimensions":{"congress":"European Respiratory Society (ERS) Congress 2026","congress_dates":"Sept. 5-9, 2026, Barcelona","encore_regimen":"ARIKAYCE plus azithromycin 250 mg and ethambutol 15 mg/kg","abstracts_accepted":5,"encore_treatment_duration_months":12}},"named_entities":{"people":[{"name":"Martina Flammer, M.D., MBA","role":"Chief Medical Officer of Insmed"},{"name":"Sara Bonstein","role":"Chief Financial Officer (investor contact)"},{"name":"Claire Mulhearn","role":"Vice President, Corporate Communications (media contact)"}],"products":["ARIKAYCE (amikacin liposome inhalation suspension)","BRINSUPRI (brensocatib)","TPIP (treprostinil palmitil inhalation powder)","Lamira Nebulizer System","PULMOVANCE liposomal technology"],"companies":[{"name":"Insmed Incorporated","ticker":"INSM","relationship":"filer"},{"name":"PARI Pharma GmbH","relationship":"device partner (Lamira Nebulizer System manufacturer)"},{"name":"European Respiratory Society","relationship":"congress organizer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-03T11:12:32.865Z","global_importance":25,"audience_relevance":40,"importance_components":{"tickerTier":"mid/large-cap commercial-stage biotech","eventGravity":"conference data preview — no results disclosed","issuerAuthored":true,"catalystProximity":"late-breaking ENCORE data presented Sept. 6, three days after release","retailFavoriteBoost":"moderate — INSM has an active biotech retail following around ARIKAYCE/BRINSUPRI/TPIP catalysts"}},"durationMs":164831,"modelName":"glm-4.7"}}